Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Food and Metabolism Study (FAM)

Effects of Avocado on Triglyceride Metabolism in Individuals With Insulin Resistance

In this study, Investigators are interested in looking at the influence of eating avocados regularly, which are rich in healthy fats, fibers, and unique carbohydrates, on triglyceride and glucose metabolism in people with prediabetes and insulin resistance.

Visão geral do estudo

Descrição detalhada

The proposed study will be conducted in humans according to Good Clinical Practice (GCP) guidelines. All subjects will review and sign an Informed Consent Form approved by the Illinois Institute of Technology's Institutional Review Boards (IRB) prior to screening. The research is designed as a randomized, 2-arm, parallel, diet-controlled, human clinical trial to investigate the effects of avocado consumption for 4 weeks on triglyceride metabolism in individuals with insulin resistance.

Participants will be asked to do the items described below. Visits will be held at the Clinical Nutrition Research Center (CNRC) on the Illinois Tech Campus, 10 W. 35th St., Suite 3D6-1 Chicago, IL, 60616.

SCREENING VISIT

Eligibility for the study is based on the above list (inclusion and exclusion criteria). Investigators will determine if participants qualify for the study at the Screening Visit by the following measurements:

  • General measurements: height, weight, body composition, waist circumference, blood pressure, vitals and body temperature
  • Fasting blood glucose (sugar) from a finger prick
  • Venous blood collection to assess blood glucose, insulin, and triglycerides
  • Pregnancy test, for women under the age of 60

Demographic questionnaire, health and medication questionnaire: participants will be asked to provide personal information, such as their name, date of birth, race, etc. Investigators will also ask them to answer questions about their demographics, health, medical history, and the medications they are taking. Based on the results of the blood draw, questionnaires, measurements, and evaluation of their health, they may meet the criteria and be invited to participate in the study.

PRE-STUDY / PRE-INTERVENTION VISIT (which may be performed on the same or a different day as the screening visit) The Pre-Study visit lasts ~45 minutes to 1 hour and participants will meet with one of our investigators who will provide detailed instructions on procedures of the study and "how to prepare for each of participants study days." They will be trained in all study procedures, including, but not limited to, foods to avoid during the study, medications/supplements to avoid, food diary recording, gastrointestinal diary recording and fasting overnight. Their study dates will be scheduled, and they will be provided with a study booklet, including a study calendar and all instructions covered at the Pre-Study Visit.

Medications/Supplements: If they are taking any medications or supplements that do not interfere with the study or have been OK'd by study staff, they will take those as instructed by their doctor and will record them in their diary. Investigators will train the participants on what foods or supplements are OK and NOT OK during the study at the Pre-Study Visit.

Self-Characteristics and Dietary Surveys: Participants will be asked to complete online surveys that cover usual gastrointestinal symptoms and a 24-hour food recall (https://asa24.nih.gov/).

STUDY DAY VISITS Study Visit 1 / Day 0 and Visit 5 / Day 28 Procedures

Staff collects study materials from the participant

1. Diary and provide 24 h recall (https://asa24.nih.gov/) Confirmation participant is ready to go for their study day by interview/discussion with the study staff

  1. Fasted overnight for 10-12 hours, including finger prick to verify usual fasting glucose
  2. Had a usual night of sleep (5-6 hours minimum)
  3. Avoided alcohol and vigorous physical activity 24 hours before the study day

After confirming they are ready for their study day, Investigators will proceed to an exam room to measure:

Anthropometrics: Investigators will measure weight, waist circumference and body composition.

Vital signs: Investigators will check their blood pressure, heart rate, and body temperature using standard clinic devices.

Once Investigators have collected measurements, they will proceed with an IV catheter to collect blood over multiple timepoints.

Blood collection: Participants will see the Licensed Health Care Provider (LHCP) for blood sample collection. Investigators will use an indwelling catheter (IV). This means Investigators will use a needle to put a thin tube in their arm or hand, from which Investigators can get blood samples while keeping them as comfortable as possible. This tube will stay in their arm until all blood drawings are completed during their visit. If there is difficulty with blood flow Investigators will ask the participant if they're comfortable with single stick blood collection, performed by LHCP using a butterfly needle. There will be nine blood draws in total over 5 hours.

Once the fasting blood draw is collected, Investigators will provide the participant with a breakfast in the form of a nutritionally complete liquid meal test (LMT).

Standard Liquid Meal Test (LMT): For this test, they will drink about 2 cups of vanilla flavored Ensure®. Ensure® is a nutritional supplement containing a mixture of sugars, fats, and protein and a variety of vitamins and minerals. The drink contains milk protein (suitable for lactose intolerance) and soy products. Investigators will ask if they are unwilling to consume any ingredients in the Ensure® drink. It may be unsafe for them to complete this test if they have an allergy to any of the components. The total amount participant will drink will be approximately 440 calories, 64g of Carbs, 12g of Fat, and 18g of Protein.

After all blood samples have been collected they will be provided with meals to last until V2 (~ 1 week) and instructed how to fill out the dietary adherence log.

MEAL PICKUP VISITS Study Visit 2 / Day 7, Study Visit 3 / Day 14, Study Visit 4 / Day 21

Participants will not need to come fasted for meal pickup visits. Investigators will collect materials and ensure they are complying with the study protocols, and assess if there are any difficulties Investigators can help with. The following will be done at pickup visits:

Staff collects study materials from the participant 1. Diary and provide 24 h recall (https://asa24.nih.gov/) Staff collects weight and LDN does counseling as needed

1. Licensed Dietitian Nutritionist (LDN) will review compliance diary and weight changes and provide nutrition counseling as needed

Tipo de estudo

Intervencional

Inscrição (Estimado)

82

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Estude backup de contato

Locais de estudo

    • Illinois
      • Chicago, Illinois, Estados Unidos, 60616
        • Recrutamento
        • Clinical Nutrition Research Center at IIT

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

  • Adulto
  • Adulto mais velho

Aceita Voluntários Saudáveis

Sim

Descrição

Inclusion Criteria:

  • Men or women, 40-70 years of age.
  • Fasting triglycerides (TG) >115 mg/dL.
  • Insulin resistance as measured by Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) >2.5.
  • Able to provide informed consent.
  • Able to comply with and perform the procedures requested by the protocol, specifically eat all the meals and snacks provided by the study which will be almost all your food (~ 80% of calories per day).
  • Able to come to the clinic up to 6 times during the study.
  • Able to maintain usual physical activity pattern.
  • Able to avoid/abstain from alcohol and vigorous physical activity for 24 hours prior to and during study visit.

Exclusion Criteria:

  • Men and women with known or suspected intolerance, allergies or hypersensitivity to study foods or interventions.
  • Fasting blood sugar ≥125 mg/dL. Men and women with blood pressure >160 mmHg (systolic) / 100 mmHg (diastolic) at the screening visit.
  • Men and women with history of diabetes cardiovascular events, respiratory, renal, gastrointestinal, hepatic or eye disease or surgery- within a year.
  • Men and women who have or had cancer other than non-melanoma skin cancer in the past 5 years.
  • Men and women taking over the counter or prescription medications or dietary supplements that may interfere with study procedures or endpoints.
  • Men and women who are on a specialized diet (vegan, vegetarian, keto, etc.). - - Men and women who consume nuts or peanuts daily or most days of the week.
  • Men and women who are not weight stable (+/-10lbs in previous 2 months). Men and women who have excessive use of drugs or alcohol (ie., addictions) within the past 2 years.
  • Men and women with documented physical or mental disease/condition, which might limit participation in or completion of the study or, that, in the opinion of the investigator, could interfere with the interpretation of the study results.
  • Women who are known to be pregnant or who are intending to become pregnant over the course of the study.
  • Women who are lactating.
  • Major trauma or a surgical event within 2 months (or longer depending on trauma or event) and after consultation with PI. Has used antibiotics within the previous 2 months.
  • History of an eating disorder (e.g., anorexia nervosa, bulimia nervosa, or binge eating) diagnosed by a health professional.
  • Excessive coffee and tea consumers (> 4 cups/d).
  • Donated blood within the last 3 months.
  • Women who are taking an unstable dose and brand of hormonal contraceptives and/or a stable dose and brand for less than 6 months.
  • Unusual working hours (working overnight).

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Prevenção
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Solteiro

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Comparador Ativo: Avocado meal plan
2 meals and snack per day including one avocado in the meal, covering 80% of daily calories need.
American Diet with avocado
Comparador de Placebo: Control meal plan
2 meals and snacks per day without the inclusion of avocado, covering 80% of daily calories needs.
American diet

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Changes in serum biomarker: triglycerides
Prazo: baseline and 4 weeks
analyzed by McLendon labs
baseline and 4 weeks

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Changes in serum biomarker: insulin
Prazo: baseline and 4 weeks
analyzed by McLendon labs
baseline and 4 weeks
Changes in serum biomarker: glucose
Prazo: baseline and 4 weeks
analyzed by McLendon labs
baseline and 4 weeks
Changes in Muscle Insulin Sensitivity Index (MISI)
Prazo: baseline and 4 weeks
calculated using postprandial glucose and insulin concentrations measured by Randox clinical analyzer
baseline and 4 weeks
Changes in total cholesterol
Prazo: baseline and 4 weeks
fasting state, analyzed by Labcorp
baseline and 4 weeks
Changes in free fatty acids
Prazo: baseline and 4 weeks
analyzed by Quest Diagnostics Lab
baseline and 4 weeks
Fructosamine
Prazo: baseline and 4 weeks
analyzed by Randox clinical analyzer
baseline and 4 weeks
Changes in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)
Prazo: baseline and 4 weeks
Calculated from fasting glucose and insulin
baseline and 4 weeks
Changes in Low-Density Lipoprotein (LDL) cholesterol
Prazo: baseline and 4 weeks
fasting state, analyzed by Labcorp
baseline and 4 weeks
Changes in High-Density Lipoprotein (HDL) cholesterol
Prazo: baseline and 4 weeks
fasting state, analyzed by Labcorp
baseline and 4 weeks
Changes in non-High-Density Lipoprotein (HDL) cholesterol
Prazo: baseline and 4 weeks
fasting state, analyzed by Labcorp
baseline and 4 weeks
Changes in Connecting Peptide (C-peptide)
Prazo: baseline and 4 weeks
analyzed by McLendon labs
baseline and 4 weeks
Changes in Glucagon-Like Peptide-1(GLP-1)
Prazo: baseline and 4 weeks
analyzed by Luminex multi-target analyzer
baseline and 4 weeks
Inflammation markers-Interleukin (IL)-6
Prazo: Baseline
Analyzed by Luminex method
Baseline
Inflammation markers-Interleukin (IL)-10
Prazo: Baseline
Analyzed by Luminex method
Baseline
Inflammation markers-Tumor necrosis factor alpha (TNF-α)
Prazo: Baseline
Analyzed by Luminex method
Baseline
Nuclear Magnetic Resonance (NMR) Lipoprotein Subfraction
Prazo: Baseline
Analyzed by Labcorp
Baseline

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Colaboradores

Investigadores

  • Investigador principal: Britt Burton-Freeman, PhD, Food Sci and Nut Programs

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

3 de junho de 2026

Conclusão Primária (Estimado)

28 de junho de 2027

Conclusão do estudo (Estimado)

31 de dezembro de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

28 de maio de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

28 de maio de 2026

Primeira postagem (Real)

3 de junho de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

1 de julho de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

29 de junho de 2026

Última verificação

1 de junho de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

We would make all de-identified IPD collected during the trial (i.e., the study outcomes) publicly available upon request.

Prazo de Compartilhamento de IPD

January 1, 2028-no end date

Critérios de acesso de compartilhamento IPD

A steering committee composed of primary investigators from the study approves or denies research proposals.

Tipo de informação de suporte de compartilhamento de IPD

  • PROTOCOLO DE ESTUDO
  • SEIVA
  • CIF
  • ANALYTIC_CODE

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever